8-K: Interpace Biosciences Receives Delay in Medicare Coverage Determination, Re-evaluates Restructuring Plan

Interpace Biosciences announces a delay in the implementation of a Medicare coverage determination that would have impacted its PancraGEN test, leading the company to re-evaluate its restructuring plan.

Summary

• Interpace Biosciences announced that the Centers for Medicare & Medicaid Services (CMS) has delayed the implementation of the Genetic Testing for Oncology Local Coverage Determination (LCD) from February 23, 2025, to April 24, 2025.
• This delay allows the incoming Trump administration time to review the policy changes and the clinical evidence supporting the PancraGEN assay.
• As a result of this delay, Interpace is re-evaluating its previously announced restructuring plan, which was initiated due to the anticipated loss of coverage for PancraGEN.
• The company will determine which parts of the restructuring plan will be postponed.
• Interpace will continue to offer PancraGEN and related fluid chemistry tests during this extension.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the delay in the LCD implementation, which allows Interpace to continue offering PancraGEN. However, the underlying uncertainty regarding future coverage and the need for a restructuring plan temper the positive outlook.

Positives

• The delay in the LCD implementation allows Interpace to continue offering PancraGEN.
• The company can re-evaluate its restructuring plan and potentially avoid job losses.
• Interpace has the opportunity to present further evidence supporting the clinical utility of PancraGEN to the incoming administration.
• PancraGEN has a long history of Medicare coverage and has benefited a large number of patients.

Negatives

• The initial restructuring plan was put in place due to the anticipated loss of coverage for PancraGEN, indicating a potential vulnerability in the company's revenue stream.
• The future of PancraGEN coverage remains uncertain, pending further review by the incoming administration.

Risks

• The reimbursement of Interpace's tests is subject to review by CMS.
• The company's ability to continue performing, billing, and receiving reimbursement for PancraGEN is uncertain.
• Estimates of future revenue, cash flows, and adjusted EBITDA may prove to be inaccurate.
• The company has a prior history of operating losses.
• The company's ability to adequately finance its business and repay borrowings is a risk.

Future Outlook

The company will use the additional time to work with the incoming administration to demonstrate that there has not been any new evidence to justify non-coverage of PancraGEN.

Management Comments

• Tom Burnell, President and CEO of Interpace, stated that the company is grateful for the delay on behalf of patients and physicians who rely on PancraGEN.
• Burnell added that the extension allows Interpace to continue offering PancraGEN and related tests, and supports the employees who process specimens.

Industry Context

The announcement highlights the ongoing challenges and uncertainties surrounding reimbursement for molecular diagnostic tests, particularly in the context of changing healthcare policies and regulatory reviews.

Comparison to Industry Standards

• It is difficult to compare Interpace's situation directly to industry standards without knowing the specific details of the clinical evidence and cost-effectiveness data for PancraGEN.
• However, the company's reliance on a single test for a significant portion of its revenue is a risk factor, as is the dependence on Medicare reimbursement.
• Other diagnostic companies with more diversified product portfolios and broader payer coverage may be less vulnerable to changes in coverage determinations.

Stakeholder Impact

• The delay in the LCD implementation benefits patients by allowing continued access to PancraGEN.
• It also benefits employees by potentially avoiding job losses.
• Shareholders may experience short-term relief, but the long-term impact depends on the outcome of the coverage review.

Next Steps

• Interpace will re-evaluate its restructuring plan.
• Interpace will work with the incoming administration to further demonstrate the clinical utility of PancraGEN.

Key Dates